Amgen Adopts Technology Solution For Antibody Discovery And Cell Line Development

As one of the early customers to have adopted the Berkeley Lights platform, Amgen has been able to continuously push the capabalities of the Beacon® optofluidic system. Since adoption, Amgen has expanded their usage of the platform from antibody discovery to cell line development. By putting it into practice in their antibody discovery work they were able to take about four months off the normal timeline. They have also implemented the system as their standard method for cell line development, and are looking to extend their success in these areas to other applications. Continue reading to learn more about this transformative tool.